Guardant Health Acquires MetaSight Diagnostics for $150M

Guardant Health, a prominent player in precision oncology, has significantly expanded its diagnostic arsenal by acquiring MetaSight Diagnostics for a potential total of $150 million. This strategic move, comprising an initial $59 million cash payment and up to $90 million in performance-based tranches, signals a robust commitment to advancing early cancer detection and broader disease identification through innovative liquid biopsy technologies.

The acquisition brings MetaSight Diagnostics, an Israeli startup founded by Professor Tomer Shlomi of the Technion, into Guardant Health's fold. MetaSight distinguishes itself by employing a proprietary multiomics strategy that integrates mass spectrometry with metabolomics, lipidomics, and proteomics, amplified by artificial intelligence. This approach diverges from the prevalent next-generation sequencing methods, offering a potentially more sensitive and cost-effective pathway for identifying disease biomarkers in serum samples.

This transaction is particularly noteworthy for its strategic implications. Guardant Health intends to establish MetaSight's facility in Rehovot, Israel, as its inaugural international research and development hub. This decision underscores the company's confidence in Israel's vibrant innovation ecosystem and its capacity to drive advancements in diagnostic technologies. The move also broadens Guardant's reach beyond its existing US-centric operations.

MetaSight's pipeline includes promising tests for colorectal cancer, a critical focus area for Guardant Health, and for detecting liver disease-associated fibrosis. The company's technology, developed in collaboration with the aMoon venture fund and leveraging a substantial database of nearly one million samples from Maccabi Health Fund, promises rapid, high-resolution diagnostics at a remarkably low per-test cost, potentially just a few dollars. This efficiency is a key differentiator in the competitive diagnostics market.

Founded in 2020, MetaSight had previously secured approximately $20 million in funding from a diverse group of investors, including aMoon Growth Fund, ARC Fund, and Saban Ventures, alongside a grant from the Israel Innovation Authority. The acquisition is anticipated to yield substantial returns for these early-stage backers, validating their investment in MetaSight's novel technological platform.

For Guardant Health, which reported nearly $1 billion in recent annual revenue and projects sales between $1.25 billion and $1.28 billion for 2026, this acquisition is more than just an expansion of capabilities. It represents a strategic enhancement of its existing Shield product line, which utilizes next-generation sequencing. By integrating MetaSight's mass spectrometry-based platform, Guardant can now offer a more comprehensive suite of tools for multi-cancer early detection and extend its diagnostic reach into a wider spectrum of diseases. The global liquid biopsy market, projected to exceed $10 billion by 2030, presents a significant growth opportunity that this deal is well-positioned to capitalize on.